Intra-Cellular Therapies, Inc. (ITCI) Financial Statements
Intra-Cellular Therapies, Inc. (ITCI) files with the U.S. Securities and Exchange Commission under CIK 0001567514. 10KGenie shows its annual and quarterly statements from SEC filings.
Key Figures, Fiscal Year 2024
- Revenue
- $680.85 million
- Net Income
- -$74.68 million
- Total Assets
- $1.37 billion
- Net Cash from Operations
- -$73.18 million
Fiscal year ended Dec 31, 2024. Latest periodic SEC filing: Mar 20, 2025. Source: SEC filings (EDGAR XBRL).
Open the full financial statements for ITCI in 10KGenie
Data from SEC EDGAR filings. 10KGenie is not affiliated with the SEC. SEC Filing History